Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T. Penault-Llorca F, et al. Among authors: cayre a. ESMO Open. 2024 May;9(5):103443. doi: 10.1016/j.esmoop.2024.103443. Epub 2024 Apr 30. ESMO Open. 2024. PMID: 38692082 Free PMC article. Clinical Trial.
[Assessment of HER2 status in breast cancer].
Penault-Llorca F, Cayre A. Penault-Llorca F, et al. Among authors: cayre a. Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Bull Cancer. 2004. PMID: 15899610 Free article. Review. French.
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Hequet D, Hajjaji N, Charafe-Jauffret E, Boucrauta A, Dalenc F, Nicolai V, Lopez J, Tredan O, Deluche E, Fermeaux V, Tixier L, Cayre A, Menet E, Lerebours F, Rouzier R. Hequet D, et al. Among authors: cayre a. Cancer Med. 2023 Aug;12(16):16889-16895. doi: 10.1002/cam4.6315. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409516 Free PMC article.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Ginzac A, Molnar I, Durando X, Motte Rouge T, Petit T, D'hondt V, Campone M, Bonichon-Lamichhane N, Venat Bouvet L, Levy C, Augereau P, Pistilli B, Arsene O, Jouannaud C, Nguyen S, Cayre A, Tixier L, Mahier Ait Oukhatar C, Nabholtz JM, Penault-Llorca F, Mouret-Reynier MA. Ginzac A, et al. Among authors: cayre a. Breast Cancer Res Treat. 2024 Jun;205(2):267-279. doi: 10.1007/s10549-024-07285-y. Epub 2024 Mar 7. Breast Cancer Res Treat. 2024. PMID: 38453781 Free PMC article. Clinical Trial.
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Nabholtz JM, Chalabi N, Radosevic-Robin N, Dauplat MM, Mouret-Reynier MA, Van Praagh I, Servent V, Jacquin JP, Benmammar KE, Kullab S, Bahadoor MR, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon YJ, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Among authors: cayre a. Int J Cancer. 2016 May 1;138(9):2274-80. doi: 10.1002/ijc.29952. Epub 2015 Dec 28. Int J Cancer. 2016. PMID: 26649807 Clinical Trial.
81 results